JAB BX 300
Alternative Names: JAB-BX-300Latest Information Update: 01 Sep 2023
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Leukaemia inhibitory factor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 Apr 2023 Preclinical trials in Solid tumours in China (Parenteral) prior to April 2023
- 04 Apr 2023 The Center for Drug Evaluation of the National Medical Products Administration (NMPA) of China approves IND application for JAB BX300 in Solid tumours
- 04 Apr 2023 Jacobio Pharma plans a phase I/IIa trial for Solid tumours (Late-stage disease) in China (PO)